General Intermediates of Canada Inc.
$233,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2018-2019
- Agreement period
- July 1, 2018 – February 29, 2020
- Reference
- nrc-cnrc:172-2018-2019-Q2-909375
Published purpose
The proposed project involves Stage 1 drug discovery program on synthetic anticancer nucleosides based on Firm's existing technology platform in nucleoside chemistry including a library of nucleoside based molecules, many of which have been of interest to the pharmaceutical industry. Objective is to develop and screen a series of synthetic nucleosides, identify lead candidates and fully characterize them for anticancer properties on human cancer cell lines. Ultimate goal is to discover proprietary anticancer drug candidate/s with high therapeutic index for consideration as a pharmaceutical within the synthetic anticancer nucleosides drug class.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.